Pneumococcal infection in adults: burden of disease.

To overview the present global burden of pneumococcal disease is important because new preventive measures such as the pneumococcal conjugate vaccine 13 are currently being evaluated. Pneumococcal disease is roughly divided into non-invasive and invasive disease. The burden of non-invasive pneumococcal disease in adults is mainly determined by community-acquired pneumonia. Pneumococcal pneumonia has high incidence rates and carries a high mortality risk, especially in the elderly. Within the cluster of invasive pneumococcal diseases, pneumonia also represents the most common infectious source. Incidence and mortality rates of both non-invasive and invasive disease have changed as a result of pneumococcal vaccination in children. However, especially elderly patients with comorbidities remain vulnerable to morbidity and mortality caused by pneumococcal disease. The current review summarizes the current knowledge on the epidemiology including outcome of the main clinical forms of pneumococcal disease, with a special focus on elderly patients. Furthermore, the economic burden and future vaccine strategies are briefly discussed.

[1]  C. Rock,et al.  Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[2]  L. Jackson,et al.  Clinical and economic burden of pneumococcal disease in older US adults. , 2010, Vaccine.

[3]  M. Niederman.  Community-acquired pneumonia: the U.S. perspective. , 2009, Seminars in respiratory and critical care medicine.

[4]  T. Rodríguez-Blanco,et al.  Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases , 2012, Human vaccines & immunotherapeutics.

[5]  D. Grobbee,et al.  Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. , 2008, The Netherlands journal of medicine.

[6]  T. Schaberg,et al.  Guidelines for the management of adult lower respiratory tract infections ‐ Full version , 2011, Clinical Microbiology and Infection.

[7]  P. Paradiso.  Pneumococcal Conjugate Vaccine for Adults: A New Paradigm , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Weiskopf,et al.  Biology of immune responses to vaccines in elderly persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  H. Campbell,et al.  Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  T. Welte,et al.  Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study , 2011, Thorax.

[11]  T. Marrie,et al.  Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. , 2000, The Journal of infectious diseases.

[12]  The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  T. Lieu,et al.  Healthcare utilization and cost of pneumococcal disease in the United States. , 2011, Vaccine.

[14]  P. Durando,et al.  Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine. , 2012, Journal of preventive medicine and hygiene.

[15]  I. Bolíbar,et al.  Epidemiology of community-acquired pneumonia in adults: a population-based study. , 2000, The European respiratory journal.

[16]  M. Mantero,et al.  Understanding the burden of pneumococcal disease in adults. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  B. Nunes,et al.  Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009 , 2012, European Respiratory Journal.

[18]  T. Welte,et al.  Clinical and economic burden of community-acquired pneumonia among adults in Europe , 2010, Thorax.

[19]  J. Oosterheert,et al.  Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  T. Rodríguez-Blanco,et al.  Epidemiology of community-acquired pneumonia in older adults: a population-based study. , 2009, Respiratory medicine.

[21]  A. Schuchat,et al.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.

[22]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[23]  S. Soimakallio,et al.  Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. , 1993, American journal of epidemiology.

[24]  Young Keun Kim,et al.  Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study , 2013, BMC Infectious Diseases.

[25]  J. Vaupel,et al.  Ageing populations: the challenges ahead , 2009, The Lancet.

[26]  P. Hsueh,et al.  Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. , 2011, International journal of antimicrobial agents.

[27]  F. Herrero,et al.  Microbiology and Risk Factors for Community-Acquired Pneumonia , 2012, Seminars in Respiratory and Critical Care Medicine.

[28]  T. Welte,et al.  Community-acquired pneumonia in younger patients is an entity on its own , 2011, European Respiratory Journal.

[29]  R. Hubbard,et al.  Pneumonia mortality in a UK general practice population cohort. , 2009, European journal of public health.

[30]  A. Chandran,et al.  The Worldwide Impact of the Seven-valent Pneumococcal Conjugate Vaccine , 2012, The Pediatric infectious disease journal.

[31]  Tania García-Zenón,et al.  Community-acquired pneumonia in the elderly , 2013 .

[32]  J. Rello,et al.  Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  F. Blasi,et al.  Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. , 2013, Chest.

[34]  P. Balmer,et al.  The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review , 2013, Advances in Therapy.

[35]  Matthew R Moore,et al.  Aging population and future burden of pneumococcal pneumonia in the United States. , 2012, The Journal of infectious diseases.

[36]  D. Feikin,et al.  Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  T. Welte,et al.  Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network , 2009, Seminars in respiratory and critical care medicine.

[38]  P. Beutels,et al.  Economic Aspects of Pneumococcal Pneumonia , 2012, PharmacoEconomics.

[39]  T. Welte,et al.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality , 2009, Thorax.

[40]  T. Wiemken,et al.  Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. , 2013, Respiratory medicine.

[41]  Barrett T. Kitch,et al.  Trends in Mortality and Medical Spending in Patients Hospitalized for Community-Acquired Pneumonia: 1993–2005 , 2010, Medical care.

[42]  N. Andrews,et al.  Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. , 2011, The Lancet. Infectious diseases.

[43]  I. Hung,et al.  Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[44]  A. Gennery,et al.  Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia , 2012, Epidemiology and Infection.

[45]  J. Stuart,et al.  Increasing Hospital Admissions for Pneumonia, England , 2008, Emerging infectious diseases.

[46]  M. Mufson,et al.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. , 1999, The American journal of medicine.

[47]  B. Henriques Normark,et al.  Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia , 2013, Thorax.

[48]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[49]  A. Anzueto,et al.  Long-term prognosis in community-acquired pneumonia , 2013, Current opinion in infectious diseases.

[50]  A. Torres,et al.  Community-acquired pneumonia in outpatients: aetiology and outcomes , 2012, European Respiratory Journal.

[51]  L. Baddour,et al.  Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  K. O'Brien,et al.  Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques , 2013, PloS one.

[53]  R. Holman,et al.  Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. , 2005, JAMA.

[54]  I. Cifuentes,et al.  Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain) , 2012, BMC Infectious Diseases.

[55]  W. Schaffner,et al.  Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  G. Pera,et al.  A population-based study of the costs of care for community-acquired pneumonia , 2004, European Respiratory Journal.

[57]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[58]  T. Welte,et al.  Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment , 2008, European Respiratory Journal.

[59]  A. Schuchat,et al.  Epidemiology of Pneumococcal Infections in the Elderly , 1999, Drugs & aging.

[60]  A. El‐Solh,et al.  Etiology of severe pneumonia in the very elderly. , 2001, American journal of respiratory and critical care medicine.

[61]  J. Lynch,et al.  Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention , 2009, Seminars in respiratory and critical care medicine.

[62]  Á. Gentile.  [U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination]. , 2014, Archivos argentinos de pediatria.

[63]  M. Dickson,et al.  Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP) , 2010, Journal of medical economics.

[64]  M. Kolczak,et al.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. , 1997, Archives of internal medicine.

[65]  A. Torres,et al.  Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.

[66]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[67]  T. Welte,et al.  Cost analyses of community-acquired pneumonia from the hospital perspective. , 2005, Chest.

[68]  H. Raspe,et al.  Approaches to estimate the population-based incidence of community acquired pneumonia. , 2007, The Journal of infection.

[69]  B. Spratt,et al.  Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. , 2003, The Journal of infectious diseases.

[70]  F. Sorvillo,et al.  Declining invasive pneumococcal disease mortality in the United States, 1990-2005. , 2010, Vaccine.

[71]  S. Richter,et al.  Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–2011 , 2013, Emerging infectious diseases.

[72]  S. Kaplan,et al.  Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine , 2013, The Pediatric infectious disease journal.

[73]  M. Steinhoff,et al.  Invasive pneumococcal disease associated with high case fatality in India. , 2013, Journal of clinical epidemiology.

[74]  W. Thompson,et al.  The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  M. P. van der Linden,et al.  Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[76]  G. Rohde,et al.  The remaining challenges of pneumococcal disease in adults , 2012, European Respiratory Review.